Semaglutide 是人胰高血糖素样肽-1 的一个长效类似物， 是人胰高血糖素样肽-1 (GLP-1) 受体的激动剂。Semaglutide 有潜力用于 2 型糖尿病的研究。

Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.

Solid

GLP-1 receptor.

Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib, Arg) and is derivatized at lysine 26. The GLP-1R affinity of Semaglutide is 0.38±0.06 nM. Semaglutide is a GLP-1 analogue with 94% sequence omology to human GLP-1. has not independently confirmed the accuracy of these methods. They are for reference only.

The plasma half-life of Semaglutide is 46h in mini-pigs following i.v. administration and semaglutide has an MRT of 63.6h after s.c. dosing to mini-pigs. Semaglutide improves 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced motor impairments. In addition, Semaglutide rescues the decrease of tyrosine hydroxylase (TH) levels, alleviates the inflammation response, reduces lipid peroxidation, inhibits the apoptosis pathway, and also increases autophagy- related protein expression, to protect dopaminergic neurons in the substantia nigra and striatum. Moreover, the long-acting GLP-1 analogue semaglutide is superior to NN-2211 in most parameters. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisturePowder -80°C 2 years；-20°C 1 year

[1]. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844.
[2]. Zhang L, et al. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinsons disease mouse model. Neuropeptides. 2018 Oct;71:70-80.

In Vitro: H₂O : 12.5 mg/mL (3.04 mM; ultrasonic and adjust pH to 2 with HCl)DMSO : 5 mg/mL (1.22 mM; ultrasonic and warming and heat to 60°C)